Our Stocks to Watch tomorrow include XTend Medical Corp. (OTC: XMDC), IGSM Group Inc. (OTC: IGSM), eWorld Companies Inc. (OTC: EWRC), CAPE Systems Group Inc. (OTC: CYSG), Dana Resources Inc. (OTCBB: DANR) and Advaxis Inc. (OTCBB: ADXS).
XTEND MEDICAL CORPORATION (OTC: XMDC)
"Up 375.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/XMDC.php
XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis.
XMDC News:
October 1 - XTend Medical Signs Letter of Intent to Merge With BioHarp, Korea Combined Resources to Target Global Health Markets
XTend Medical Corp. (OTC: XMDC), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, announced today the company has signed a Letter of Intent to Merge with BioHarp Korea, a division of Uni Bio-Tech, Inc, a Seoul, Korea based developer and manufacturer of medical imaging devices. Under the terms of the merger, BioHarp
BioHarp is a cutting-edge medical imaging device that utilizes a non-invasive approach to detect inflammation in the human body on a cellular level. The device uses a complex scanning program that deciphers inflammation in the body's organs through a bio-sensory system and allows early detection and diagnosis of potentially life threatening diseases. This hand-held diagnostic device is the first of its kind that can effectively scan the body and deliver a comprehensive report that can assist any physician in determining the proper course of treatment for patients in the EARLY STAGES of potentially life threatening diseases.
Unlike CT Scans, MRIs and other similar testing devices, the BioHarp penetrates to the cellular level to detect inflammation differences in the cells. The resulting scan of the body can detect early disease states such as diabetes, liver damage, and other organ problems that, when treated at this early stage, can assist managed care companies, physicians, and insurance companies in increasing morbidity rates and lowering health costs significantly.
The U.S. National Science Foundation has predicted that the market for nanotechnology, or products containing nanotechnology, will reach $1 trillion in 10 to 15 years. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare.
"The management at XTend has been working diligently on this merger for the past 9 months to insure we create a powerful opportunity for the company to have a clear manufacturing partner, cutting-edge medical device, and the market whereby we can sell this device globally to healthcare organizations and countries looking to detect early signs of diseases that will save lives and lessen costs associated with treating these diseases," stated Mr. Paul Lisenby, CEO of XTend Medical. Mr. Lisenby further states, "The BioHarp has gone through several revisions and is now ready to go into full production. The device is not only intended for humans, but the application has shown that animals can benefit from this technology as well. Our goal is to get this device into the hands of physicians, veterinarians, and other professionals that understand the technology can detect, on a molecular level, inflammation that can lead to serious health problems. We will market this product aggressively and have already been contacted by several countries in Asia and
IGSM GROUP INCORPORATED (OTC: IGSM)
"Up 71.43% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/IGSM.php
Based in
IGSM News:
September 30 - IGSM Outlines Large-Scale Webinar Platform
IGSM Group Inc. (OTC: IGSM) outlines its large-scale webinar platform, the first of a series of E-Learning products.
IGSM Group Inc.outlined its Large-Scale webinar platform aimed at the corporate or repeat user who uses webinars on a regular basis. Whether they need 100, 500 or 1000 people on an interactive session IGSM can fulfill their needs.
"Our niche is to provide full service to the most demanding users. Whether they are corporate trainers or focused on end user education, they need a full service company," said H. Francis Fytton, CEO of IGSM. "Working closely with several content providers has enabled us to add the features they need and don't have from existing providers," added Fytton.
IGSM Group Inc.has previously announced that it will provide Distance Learning Solutions including TeleSeminars and Webinars. E-Learning or Distance Learning products have become more popular as corporations seek to reduce overhead by eliminating travel and meeting costs.
EWORLD COMPANIES INCORPORATED (OTC: EWRC)
"Up 50.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/EWRC.php
eWorld Companies, Inc. is an online marketing & advertising technologies company that develops and markets cutting edge technologies using rich media, flash, animation and 3D graphics to help individuals and businesses market and advertise online. eWorld's revenue model consists of seven components: (1) Affiliation Fees, (2) Affiliate Monthly Subscriptions, (3) Affiliate Benefit Subscriptions, (4) Product Sales, (5) Advertising Revenues, (6) Web Development Accounts, and (7) International Licensing Fees.
EWRC News:
September 30 - eWorld Companies Rejects Purchase Offer, Schedules Conference Call for Shareholders
eWorld Companies, Inc. (OTC: EWRC) has rejected an offer from Level Vision Electronics, Ltd. to purchase all outstanding shares of eWorld stock for 1.9 cents per share. The offer had been tentatively accepted by eWorld's Board of Directors pending completion of due diligence and counsel approval. However, the offer as it currently stands failed to garner the approval of either the company's counsel or its preferred shareholders and has been rejected. The company has also scheduled a shareholder conference call with Chairman and CEO Henning Morales and its Securities Counsel for Friday, October 2 at 9:30 AM PDT. Call-in information will be posted on eWorld's website and on the Boomerang Media Station™.
Mr. Morales commented, "This decision is by no means a negative comment on Level Vision Electronics. We believe the offer was very real and attractive; however it does not adequately address the needs of the company's shareholders. This is not the first time we have been approached about a buyout offer and we don't expect it to be the last. eWorld is not actively seeking a buyout; however, the company will always consider reasonable offers, whether from Level Vision or from other suitors."
CAPE SYSTEMS GROUP INCORPORATED (OTC: CYSG)
"Up 40.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/CYSG.php
CYSG News:
October 1 -
Premier packaging technology event
CAPE Systems Group, Inc. (OTC: CYSG), a leading provider of software technology for packaging design, pallet optimization, RFID Asset Tracking, inventory and warehouse management, supply chain execution and order fulfillment, announced that it will be showcasing its latest offerings in packaging design technology, featuring sustainable "green" innovations to packaging and advanced robotic palletizing and fulfillment, along with other hi-tech solutions at the PACK EXPO Las Vegas 2009 Exhibition at the Las Vegas Convention Center from October 5 - October 7, 2009.
Dave Sasson, COO of CAPE, commented, "This is a premier show for the packaging industry and we are pleased to showcase our innovative solutions at this prestigious event, especially at a time when companies are looking more than ever to achieve additional significant cost savings, while at the same time lowering their carbon footprint and impact on the environment."
DANA RESOURCES INCORPORATED (OTCBB: DANR)
"Up 73.47% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/DANR.php
Dana Resources is a precious and base metals exploration company with offices in the
DANR News:
October 1 - Emerging Stock Report Initiates Independent Research Coverage On Dana Resources
Emerging Stock Report, a leading provider of sector specific independent investment research, has initiated coverage on Dana Resources (OTCBB: DANR). Emerging Stock Report is currently offering a complimentary trial subscription. To view the company's research go to www.emergingstockreport.com.
ADVAXIS INCORPORATED (OTCBB: ADXS)
"Up 20.54% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/ADXS.php
Based in
ADXS News:
October 1 - Updated Advaxis Phase I Survival Data Indicates Long-Term Immune Protection
23% of Cervix Cancer Patients Treated with ADXS11-001 Remain Alive 36 Months After Initial Dosing
The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection.
The patients had participated in the first human trial of a live Listeria vaccine for the treatment of advanced, recurrent, metastatic cervix cancer in women who have failed prior cytotoxic treatment. Advaxis is tracking the survival of these patients at three (3) month intervals.
These mortality figures substantially exceed the median survival rate established by the National Cancer Institute's Gynecologic Oncology Group (GOG), which varies between 3.8 and 6.2 months in studies of patients who have failed prior cytotoxic treatment including chemotherapy with various agents (GOG Protocol #127).
Earlier this year, Advaxis published in the medical journal Vaccine the fact that four (4) of thirteen (13) evaluable patients, treated with ADXS11-001, experienced tumor reductions, two (2) patients had their lesions disappear and fifty-three percent (53%) survived more than one (1) year; thus, posting a median survival rate of 347 days. Although this trial was designed to assess safety, not efficacy or survival, three (3) of the thirteen (13) patients or twenty-three percent (23%) evaluable for efficacy are still alive at over 1,000 days, post-dosing with the study drug, as of September 29, 2009.
ABOUT THE ADXS11-001 IMMUNOTHERAPY
ADXS11-001 is a therapeutic vaccine, unlike currently marketed prophylactic vaccines, that treats women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection; the most prevalent sexually transmitted disease in the US today.
Earlier this year, the US Food and Drug Administration (FDA) granted Advaxis an
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com is being compensated eight thousand dollars by a third party (Mickey Reno) for EWRC advertising and promotional services. OTCPicks.com has been compensated two thousand five hundred dollars by a third party for DANR advertising and promotional services.
